GenSight Biologics S.A.
GSGTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $3 | $5 |
| % Growth | 18.4% | -50.9% | -51.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $1 | $3 | $5 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $12 | $19 | $19 | $23 |
| G&A Expenses | $4 | $6 | $8 | $6 |
| SG&A Expenses | $4 | $7 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | $1 | $4 | $3 | $5 |
| Operating Expenses | $17 | $31 | $30 | $33 |
| Operating Income | -$16 | -$30 | -$28 | -$28 |
| % Margin | -1,054.2% | -2,343.8% | -1,078% | -533.1% |
| Other Income/Exp. Net | $2 | $3 | $0 | -$0 |
| Pre-Tax Income | -$14 | -$28 | -$28 | -$29 |
| Tax Expense | $0 | -$2 | $0 | $0 |
| Net Income | -$14 | -$26 | -$28 | -$29 |
| % Margin | -933.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS | -0.17 | -0.54 | -0.6 | -0.63 |
| % Growth | 68.5% | 10% | 4.8% | – |
| EPS Diluted | -0.17 | -0.54 | -0.6 | -0.63 |
| Weighted Avg Shares Out | 83 | 48 | 46 | 45 |
| Weighted Avg Shares Out Dil | 83 | 48 | 46 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $0 |
| Interest Expense | $2 | $3 | $3 | $2 |
| Depreciation & Amortization | $1 | $2 | $1 | $1 |
| EBITDA | -$11 | -$21 | -$27 | -$27 |
| % Margin | -757.9% | -1,648.8% | -1,036.9% | -515.5% |